PLOS ONE:强化降糖或使肥胖糖尿病患者获益

2013-02-26 PLOS ONE CDS糖尿病在线

  一项覆盖9项随机对照研究、59 197例受试者的Meta分析提示,对于体质指数(BMI)>30 kg/m2的糖尿病患者,与标准降糖方案相比,强化降糖方案可有效降低卒中发生风险。(PLoS One. 2013,8:e54465)   在被纳入的59 197例受试者中,2037例罹患卒中。分析结果显示,在整个受试人群中,与标准降糖方案相比,

  一项覆盖9项随机对照研究、59 197例受试者的Meta分析提示,对于体质指数(BMI)>30 kg/m2的糖尿病患者,与标准降糖方案相比,强化降糖方案可有效降低卒中发生风险。(PLoS One. 2013,8:e54465)

  在被纳入的59 197例受试者中,2037例罹患卒中。分析结果显示,在整个受试人群中,与标准降糖方案相比,强化降糖方案对卒中并无预防作用(RR=0.96,P=0.445)。然而,在分层分析中,对于BMI>30 kg/m2的糖尿病患者,强化降糖方案有卒中预防优势(RR=0.86,P=0.041)。

肥胖糖尿病相关的拓展阅读:


Efficacy of Intensive Control of Glucose in Stroke Prevention: A Meta-Analysis of Data from 59197 Participants in 9 Randomized Controlled Trials

Background

The efficacy of treatments that lower glucose in reducing the risk of incident stroke remains unclear. We therefore did a systematic review and meta-analysis to evaluate the efficacy of intensive control of glucose in the prevention of stroke.

Methodology/Principal Findings

We systematically searched Medline, EmBase, and the Cochrane Library for trials published between 1950 and June, 2012. We included randomized controlled trials that reported on the effects of intensive control of glucose on incident stroke compared with standard care. Summary estimates of relative risk (RR) reductions were calculated with a random effects model, and the analysis was further stratified by factors that could affect the treatment effects. Of 649 identified studies, we included nine relevant trials, which provided data for 59197 patients and 2037 events of stroke. Overall, intensive control of glucose as compared to standard care had no effect on incident stroke (RR, 0.96; 95%CI 0.88–1.06; P = 0.445). In the stratified analyses, a beneficial effect was seen in those trials when body mass index (BMI) more than 30 (RR, 0.86; 95%CI: 0.75–0.99; P = 0.041). No other significant differences were detected between the effect of intensive control of glucose and standard care when based on other subset factors.

Conclusions/Significance

Our study indicated intensive control of glucose can effectively reduce the risk of incident stroke when patients with BMI more than 30.



    

版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (0)
#插入话题

相关资讯

BMC Endocr Disord:强化降糖发生低血糖的预测因素

  德国研究者进行的一项前瞻性研究(BMC Endocr Disord. 2012 Oct 17;12(1):23)表明,低血糖是接受强化降糖治疗的2型糖尿病门诊患者的常见并发症。既往发生过低血糖、微血管疾病(如视网膜病变)和接受胰岛素治疗的患者,尤其需要注意预防低血糖发生。服用噻唑烷二酮类药物、DPP-4抑制剂与GLP-1类似物的患者发生低血糖的

Circulation:1型糖尿病强化降糖体重增加过多升高并发症危险

  近期两项前瞻性研究表明,体重增加过多(DCCT研究中)与持续增长的中心性肥胖、胰岛素抵抗、血脂异常、高血压,以及随访后期(EDIC研究中)更广泛的动脉粥样硬化相关。研究于2012年12月3日在线发表于《循环》(Circulation)杂志。   1型糖尿病(T1DM)的强化降糖治疗可减少糖尿病并发症,但可伴有体重增加过多、中心性肥胖和血脂异常。该前瞻性研究目的在于确定1型糖尿病患者糖尿病治疗

Cochrane Database Syst Rev:强化降糖可预防1型糖尿病患者神经病变进展

10%的糖尿病患者在确诊时已伴有神经病变,10年后该比例升至40%~50%。强化血糖控制可能是预防这种致残疾病的最佳干预方式,但迄今仍无相关系统综述。 为此,作者在Cochrane神经肌肉疾病组专业注册数据库、CENTRAL、MEDLINE和EMBASE上查找了对糖尿病患者强化降糖的随机对照试验。主要监测指标是根据临床分级定义的临床神经病变的每年进展,次要指标包括运动神经传导速率和定量振动测